Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.
Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.
This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.
The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.